Benzodiaxane Test

The benzodiaxane test is a method for diagnosing pheochromocytoma, which consists of intravenous administration of 10-15 ml of benzodiaxane followed by measurement of blood pressure.

The essence of the method is that benzodiaxane blocks the uptake and decarboxylation of amines in tumor cells. As a result, a large amount of catecholamines is released into the blood, which causes a sharp increase in blood pressure. Thus, if a pronounced hypertensive effect is observed after the administration of benzodiaxane, this indicates the presence of pheochromocytoma.

The benzodiaxane test has high sensitivity and specificity in the diagnosis of pheochromocytoma. Therefore, it is widely used as a screening method for detecting this tumor. However, the test can only be carried out in a hospital setting and under blood pressure control, as it is associated with the risk of developing a hypertensive crisis.

The benzodiazepine test is a method for diagnosing pheochromacytoma. It involves the intravenous administration of a benzodiazepine, which causes an increase in blood pressure. In the presence of pheochromacytoma, blood pressure increases significantly, which makes it possible to identify the tumor.

The method was developed in 1950 and has since been widely used for diagnosing pheochromacytomas. It is safe and non-invasive, making it a preferred diagnostic method over other methods. However, like any other diagnostic method, the benzodiazepine test should be carried out under the supervision of a physician.